The human γ1-herpesvirus Epstein-Barr virus (EBV) and its close relatives in Old World primates have evolved a unique ability to colonise the B-lymphoid system of their hosts. In the face of host immune responses, these agents persist as a reservoir of latently infected B cells from which infectious virus can occasionally be reactivated [1] . This viral strategy depends on an ability to establish at least three alternative forms of infection in the target B cells. One is a latent growth-transforming infection in which the full spectrum of virus latent-cycle proteins is expressed and the cell is driven into proliferation; the second is a more restricted form of latency in which the expression of most, if not all, of these proteins is suppressed and the virus genome is maintained as an episome in a resting cell; the third is a cytolytic infection in which the virus itself replicates, with ordered expression of its many lytic cycle genes, and infectious virus is produced. The challenge is to understand when and where these different forms of infection are used, and how the transitions between them are regulated so as to achieve efficient colonisation of the B-cell system, persistence in the host and subsequent virus transmission.
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Despite the recent generation of an animal model of γ1-herpesvirus infection [2] , our understanding of EBV's behaviour in vivo is still limited. Certain insights have come from studies of patients suffering from infectious mononucleosis as a result of a primary EBV infection. During the acute disease, there is local replication of the orally transmitted virus in the pharynx, but then the infection appears to spread throughout the lymphoid system via the clonal expansion of latently infected, growth-transformed B cells. Lymphoblasts expressing markers of transformation by EBV, such as the latent-cycle proteins EBNA2 and LMP1, can be detected in the tonsillar lymphoid tissues of infectious mononucleosis patients [3] .
Interestingly, these lymphoblasts are not found, as might be expected, in the follicles (B-cell areas) of the lymphoid tissue or their constituent germinal centres, but in the extrafollicular areas [4] .
The presumption is that many of the virally transformed B cells are destroyed by the virus-specific cytotoxic T-cell response that peaks in the acute phase of the disease. Certainly virus loads in the B-cell pool fall dramatically as the asymptomatic virus 'carrier' state is established. Studies on long-term EBV carriers suggest that the small number of latently infected B cells that remain detectable in the blood of healthy individuals do not express EBNA2 or LMP1, have assumed a resting phenotype and are exclusively found within the minority, long-lived memory population [5] [6] [7] . How does the virus effect this transition and secure its place in B-cell memory? Is it dependent uponor can it bypass -the normally rigorous process of antigen-driven memory B-cell selection?
A recent paper from Uchida et al. [8] sheds potentially interesting new light on this question. The stimulus for their work was the earlier observation that LMP1, one of the major effectors of EBV-induced B-cell transformation, operates at least in part by recruiting and constitutively activating tumour necrosis factor (TNF) receptor-associated factors (TRAFs) in the host cell [9] . These are signaltransducing molecules used by many TNF receptor family members including CD40, a receptor expressed on the surface of B cells and involved in the cognate B-cell-T-cell interactions that underpin most antibody responses [10] . Indeed many of the proximal effects of LMP1 signalling and some of the more distal effects mirror those seen following CD40 ligation [11] . CD40-deficient mice show specific impairments in memory B-cell development. So Uchida et al. [8] set out to ask a seemingly simple question -given the overlap in signalling pathways downstream of CD40 and LMP1, can constitutive expression of LMP1 in B cells compensate for the absence of CD40?
To appreciate their findings, it is important to have some idea of the normal sequence of events comprising T-celldependent antibody responses [12] . Initially naïve B cells that have bound specific antigen move to form cognate interactions with simultaneously primed, antigen-specific CD4 + helper T cells at the border between T-cell and B-cell areas in lymphoid tissues. Following this interaction, two distinct processes occur ( Figure 1a ). T-cell help drives some activated B cells to undergo rapid but limited proliferation to form extrafollicular foci of antibody-producing plasmablasts, secreting immunoglobulins of the IgM and/or IgG isotypes. These cells use their original rearrangements of germ-line -that is, not somatically mutated -immunoglobulin genes. Virtually all antibodies produced within the first week of antigenic challenge come from this source.
Whilst this transient extrafollicular response is on-going, antigen-specific CD4 + T cells are also recruited into the follicles where cognate interactions with other antigenbearing B cells give rise to germinal centres. These are regions of clonal B-cell expansion in which somatic mutation of immunoglobulin germ-line variable regions drives intraclonal diversification of the antigen-binding site of the immunoglobulin molecule. This then allows the subsequent selection of variants with increased affinity for antigen, a process termed affinity maturation. Whereas the extrafollicular plasmablast reaction is dependent on CD4 + T cells only at its initiation, the process of B-cell selection in the germinal centre involves repeated interactions with antigen-specific CD4 + T cells. Thereafter, the selected B cells, many of which have switched from IgM to IgG or other immunoglobulin isotypes, differentiate either into long-lived, antibody-producing plasma cells or into memory B cells (Figure 1a ).
The importance of CD40 signalling to these antibody responses is clear both in mice lacking CD40 [13] and in humans lacking CD40 ligand [14] . In both cases, antigenic challenge results only in an extrafollicular IgM response, with no antibody isotype switching and no germinal centre reaction or affinity maturation (Figure 1b) . Uchida et al. [8] asked whether some or all of these defects in CD40-deficient mice could be corrected by constitutively expressing LMP1 in the B-cell lineage of these mice from a transgene [15] . As summarised in Figure 1c , they found that LMP1 expression did reconstitute some IgM to IgG class switching in the initial extrafollicular response, but did not restore germinal centre formation or the production of high-affinity antibodies [8] .
Underlying this experiment is the premise that impairment of immunoglobulin class switching, germinal centre formation and affinity maturation in CD40-deficient mice can be specifically attributed to the absence of CD40 on Dispatch R121
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The initial sites of T-and B-cell activation in the various mouse mutants. (a) Wild-type mice. Following CD4 + T-cell priming by CD40-activated dendritic cells (1) B cells, because these cells can no longer receive signals from cognate T cells delivered via CD40 ligand on the Tcell surface. It must be remembered, however, that CD40 is not restricted to the B-cell lineage but is expressed on certain other cell types, including dendritic cells -the socalled 'professional' antigen-presenting cells that are important in priming and in orientating the T-cell response (Figure 1a) . In this regard, the CD40-CD40 ligand interaction, in addition to its role in B-cell-T-cell collaboration, is one of several molecular pairings that occur sequentially at the interface between dendritic cells and T cells during T-cell priming.
In particular, CD40 signalling induces dendritic cells to upregulate co-stimulatory molecules [16, 17] , which in turn induce expression of the chemokine receptor CXCR5 on the T-cell surface. It is of interest that the ligand for CXCR5 has recently been identified and shown to be produced in B-cell follicles [18] . This chemokine might therefore mediate the specific recruitment of antigen-primed CD4 + T cells from T-cell areas into the follicles, positioning them correctly for their essential role in germinal centre formation. Whatever the effects of LMP1 on B cells, it is likely that failure to consummate this interaction between dendritic cells and T cells in the LMP1-expressing, CD40-deficient animals would remove one of the essential elements required to form a classical germinal centre.
As so often happens in science, the most interesting results from Uchida et al. [8] come from an unexpected source, in this case from the mice in which B-cell-specific expression of the LMP1 transgene was occurring in a wildtype (CD40-positive) background. These mice show small but detectable increases in B-cell surface levels of the activation antigen CD23 and the cell adhesion molecule CD54 compared with non-transgenic littermates. These cells also show enhanced levels of spontaneous and interleukin-4-induced proliferation and production of IgM and IgG in vitro. As is clear from work with human B cells [19] , however, LMP1 expression alone is insufficient to confer a growth-transformed phenotype and the LMP1 transgenic mice, at least within the first few months of life, showed no obvious abnormalities in the size, cell composition or architecture of secondary lymphoid tissues.
Following antigenic challenge, these animals mounted the initial extrafollicular B-cell response, with antigenspecific IgM and IgG production comparable to that seen in wild-type animals. Interestingly, however, the constitutive expression of LMP1 in B cells prevented germinal centre formation yet, despite this, the antibody response appeared to be of high affinity (Figure 1d ). It is not yet clear whether this reflects somatic mutation and affinity maturation occurring in the absence of conventional germinal centres, as has been reported in rare circumstances, or whether it reflects an extended life of higher affinity clones from within the germ-line-encoded extrafollicular response. The point will only be resolved by sequencing the immunoglobulin variable regions of the responding cells.
Of most immediate interest is the finding that LMP1 expression abrogates germinal centre formation. This effect is reminiscent of in vitro studies in which the LMP1 gene was ectopically expressed in EBV-negative Burkitt's lymphoma cell lines -that is, in human B cells displaying a classical germinal centre cell phenotype. One of the viral protein's numerous effects in this cell background was to block expression of Bcl6 [20] , a transcription factor that is selectively expressed in germinal centre B cells and essential for germinal centre development [21, 22] . This suggests that LMP1 actively prevents acquisition of the germinal centre phenotype.
At this point, it is worth returning to acute infectious mononucleosis patients and the observation that EBVtransformed (LMP1-expressing) B lymphoblasts are mainly found in an extrafollicular location in tonsillar tissues rather than in germinal centres or in the remainder of the follicular B-cell area [4] . The work from Uchida et al. [8] might well explain the exclusion from germinal centres, but to understand the general exclusion from follicles we again need to turn to the subject of chemokines and their control over lymphocyte migration. Just as primed CD4 + T cells are attracted to B-cell areas by upregulating the appropriate chemokine receptor CXCR5, evidence suggests that antigen-stimulated B cells can be attracted in the opposite direction by upregulating another chemokine receptor, CCR7, one of whose ligands is produced by dendritic cells in the T-cell zone of secondary lymphoid tissues [23] . Interestingly, CCR7 was first cloned as an EBV-induced (perhaps LMP1-induced?) gene in human B cells [24] . The virus may therefore dictate the extrafollicular location of its transformed cells through CCR7 upregulation.
Once primary infection is over and EBV is embedded in the memory B-cell pool, it is interesting to reflect on how the virus might again exploit B-cell migration to its own ends. Memory B cells either circulate in the bloodstream or remain resident at specific sites in lymphoid tissue, adjacent to the subepithelial sinus in tonsil, for instance [25] . On re-exposure to antigen, these memory cells again engage T cells in the extrafollicular area and proliferate extensively, giving rise both to newly formed plasma cells and to more memory cells. Such plasma cells normally relocate from lymphoid tissue to bone marrow but, in the tonsil, they also accumulate immediately below the crypt epithelium [26] . Therefore, if plasma-cell differentiation renders a cell competent to replicate EBV, as some results suggest [27] , one can imagine that antigenic re-stimulation of an EBV-infected memory cell could on the one hand direct virus replication to a mucosal site from which infectious virus can be secreted, and on the other serve to replenish the latently infected memory B-cell pool.
But these speculations skirt around some of the more immediate issues raised by the observations of Uchida et al. [8] . A number of central questions remain. What is to be gained by LMP1 diverting infected cells away from germinal centres? Is such diversion biologically important or merely a side effect of the multi-faceted LMP1 phenotype? How does the pool of EBV-transformed (LMP1-expressing) lymphoblasts generated during primary virus infection give rise to EBV-infected (LMP1-negative) memory B cells? Is there a physiological signal that the virus exploits to switch off expression of its transforming proteins at an appropriate stage of B-cell differentiation? If so, is the previous experience of viral transformation sufficient to impose a memory phenotype on the surviving cell, and would such virus-induced delivery into memory necessarily require somatic hypermutation? However difficult these questions posed by a virus from the human B-cell system, it is now a sure bet that murine models can help to answer them.
